The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

West Pharmaceutical (WST) Undervalued by 28% Amid GLP-1 Growth Surge

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

West Pharmaceutical Services (WST) is currently trading at a significant discount, with analysts estimating the stock is 28.1% undervalued relative to its fair value of $338.57. The company's growth narrative is heavily anchored in the surging demand for GLP-1 weight-loss medications and a strategic pivot toward higher-margin product lines. While the outlook remains positive, WST’s current price-to-earnings (P/E) ratio of 35.6x aligns with the North American Life Sciences average but remains higher than its direct peers. Market participants are closely watching the upcoming earnings report to gauge the company's performance within the pharmaceutical packaging supply chain. This evaluation highlights a strategic balance between strong sector tailwinds and the risks associated with high valuation multiples. As the healthcare sector evolves, West Pharmaceutical's role in supporting advanced drug delivery systems continues to be a primary driver for investor interest.